(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer mini oral session included a presentation by Dr. Richard Cathomas discussing the phase II SAAK 08/16 trial assessing darolutamide maintenance in men with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent taxane therapy. The optimal treatment sequence for mCRPC remains unclear, with cross-resistance between novel hormonal agents, however with previous studies suggesting that chemotherapy may re-induce novel hormonal agent sensitivity.